eFFECTOR Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:eFFECTOR Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11276
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
eFFECTOR Therapeutics Inc (eFFECTOR) is a clinical-stage biopharmaceutical company that focuses on the discovery and development of selective translation regulators for the treatment of cancer. Its investigational compounds are designed to restore the translational control of processes that tumors are hijacked to their benefit, preserving normal cell function. The company’s pipeline programs include tomivosertib (eFT508), a MNK1/2 inhibitor intended for the treatment of patients with solid tumors and lymphoma. It also develops selective translation regulator programs, including eIF4E, an oncogenic and historically intractable target for a variety of human cancers; and eFT226, for lymphoma. eFFECTOR is headquartered in San Diego, California, the US.

eFFECTOR Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 11
eFFECTOR Therapeutics Raises Additional USD16 Million in Series B Financing Round 13
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 14
eFFECTOR Therapeutics Raises Additional USD14.6 Million in Financing Round 16
Effector Therapeutics Raises US$45 Million In Series A Financing 17
Partnerships 19
eFFECTOR Therapeutics Enters into Agreement with Merck 19
eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 20
eFFECTOR Therapeutics Inc – Key Competitors 21
eFFECTOR Therapeutics Inc – Key Employees 22
eFFECTOR Therapeutics Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Corporate Communications 24
Mar 23, 2018: eFFECTOR Announces Appointment of John W. Smither to its Board of Directors 24
Product Approvals 25
Mar 09, 2017: Effector Therapeutics Lead Product Candidate, EFT508, Receives Orphan Designation From FDA for Treatment of Diffuse Large B-cell Lymphoma 25
Clinical Trials 26
Jul 27, 2018: eFFECTOR initiates dosing of eFT508 (tomivosertib) in a phase 2 add-on (CPI-A) trial in combination with checkpoint inhibitors to treat patients with insufficient response to checkpoint inhibitors alone 26
Jun 06, 2018: eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin’s Lymphoma 27
May 11, 2018: eFFECTOR Initiates Randomized Dosing in Phase 2 Checkpoint Combination Trial of eFT508 and Avelumab in Colorectal Cancer 28
Apr 26, 2018: eFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal Chemistry 29
Apr 16, 2018: eFFECTOR to Present Data on eFT508 at the AACR 2018 Annual Meeting 30
Dec 11, 2017: Clinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile 31
Nov 10, 2017: eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological Effects 32
Oct 04, 2017: eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer 33
Jun 05, 2017: eFFECTOR Therapeutics Presents Phase 1 Data On eFT508, Its Lead Product Candidate, At ASCO 2017 35
Apr 03, 2017: eFFECTOR Therapeutics Presents Positive Preclinical Data on Lead Product Candidate at AACR 2017 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
eFFECTOR Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 11
eFFECTOR Therapeutics Raises Additional USD16 Million in Series B Financing Round 13
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 14
eFFECTOR Therapeutics Raises Additional USD14.6 Million in Financing Round 16
Effector Therapeutics Raises US$45 Million In Series A Financing 17
eFFECTOR Therapeutics Enters into Agreement with Merck 19
eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 20
eFFECTOR Therapeutics Inc, Key Competitors 21
eFFECTOR Therapeutics Inc, Key Employees 22

List of Figures
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[eFFECTOR Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Molinos Rio de la Plata SA (MOLI3):企業の財務・戦略的SWOT分析
    Molinos Rio de la Plata SA (MOLI3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Enel Russia (ENRU):電力:M&Aディール及び事業提携情報
    Summary Enel Russia, a subsidiary of Enel Investment Holding BV, is an energy utility. It produces electricity and thermal energy. The company generates electricity using coal, gas and fuel oil sources. Enel Russia owns and operates Konakovskaya GRES, Nevinnomysskaya GRES, Reftinskaya GRES and Sredn …
  • Alberta Health Services:企業の戦略的SWOT分析
    Alberta Health Services - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Metsa Group:企業の戦略・SWOT・財務情報
    Metsa Group - Strategy, SWOT and Corporate Finance Report Summary Metsa Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Petroleo Brasileiro S.A. (Petrobras):戦略・SWOT・企業財務分析
    Petroleo Brasileiro S.A. (Petrobras) - Strategy, SWOT and Corporate Finance Report Summary Petroleo Brasileiro S.A. (Petrobras) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Darling Ingredients Inc.:企業のM&A・事業提携・投資動向
    Darling Ingredients Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Darling Ingredients Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Rising Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Rising Pharmaceuticals Inc (Rising Pharma), a subsidiary of Aceto Corp, is a manufacturer and distributor of generic prescription pharmaceutical products. The company’s products include amiloride hydrochloride, benztropine, anastrozole, carisoprodol, codeine phosphate, cetirizine hydrochlori …
  • Malakoff Corporation Berhad:発電所・企業SWOT分析
    Malakoff Corporation Berhad - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key e …
  • Stanford University-製薬・医療分野:企業M&A・提携分析
    Summary Stanford University is an educational and research organization that provides graduate and undergraduate programs. The organization’s services include education and research facilities. It provides research facilities through its research laboratories and centers. Stanford University include …
  • Otto Bock HealthCare GmbH:企業の戦略的SWOT分析
    Otto Bock HealthCare GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Nissan Chemical Corporation:企業の戦略・SWOT・財務分析
    Nissan Chemical Corporation - Strategy, SWOT and Corporate Finance Report Summary Nissan Chemical Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Lantheus Medical Imaging Inc:製品パイプライン分析
    Summary Lantheus Medical Imaging Inc (Lantheus Medical), a subsidiary of Lantheus Holdings, Inc., develops, manufactures, and commercializes diagnostic imaging agents and products for the diagnosis of conditions that affect heart, brain, lungs and other organs using echocardiography and nuclear imag …
  • MyCartis NV-医療機器分野:企業M&A・提携分析
    Summary MyCartis NV (MyCartis), formerly Pronota NV is a biomarker analysis solution provider. The company develops multiplexed biomarker solutions through evalution and bio assays technology. It uses technologies such as barcoded microparticles, microfluidic assay cartridges and evalution instrumen …
  • BYD Co Ltd (1211):企業の財務・戦略的SWOT分析
    BYD Co Ltd (1211) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Champions Oncology Inc (CSBR):企業の財務・戦略的SWOT分析
    Summary Champions Oncology Inc (Champions), formerly Champions Biotechnology Inc, is a developer of advanced technology solutions and services to personalize the development and use of oncology drugs. The company’s technology platform is an approach based upon the implantation of primary human tumor …
  • Allscripts Healthcare Solutions Inc (MDRX):医療機器:M&Aディール及び事業提携情報
    Summary Allscripts Healthcare Solutions Inc (Allscripts), formerly Allscripts-Misys Healthcare Solutions, Inc., is a provider of healthcare information technology solutions. The company’s major solutions include Electronic Health Records (EHR), Financial Management Solutions, Population Health Manag …
  • American Airlines Group Inc (AAL):企業の財務・戦略的SWOT分析
    American Airlines Group Inc (AAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Titan Cement Company Sa:企業の戦略・SWOT・財務分析
    Titan Cement Company Sa - Strategy, SWOT and Corporate Finance Report Summary Titan Cement Company Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • eGain Corp (EGAN):企業の財務・戦略的SWOT分析
    Summary eGain Corp (eGain) is a technology company that provides cloud-based and on-site customer engagement software solutions. The company offers products such as eGain case manager, eGain chat, eGain clicktocall, eGain cobrowse, eGain community, eGain consulting, and eGain virtual assistant. It a …
  • Southern Minnesota Municipal Power Agency:発電所・企業SWOT分析
    Southern Minnesota Municipal Power Agency - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, inform …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆